Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W. Angelberger S, et al. Among authors: teml a. Inflamm Bowel Dis. 2013 Mar;19(3):590-8. doi: 10.1097/MIB.0b013e31827eea8b. Inflamm Bowel Dis. 2013. PMID: 23388543
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR; International AZT-2 Study Group. Reinisch W, et al. Among authors: teml a. Gut. 2010 Jun;59(6):752-9. doi: 10.1136/gut.2009.194159. Gut. 2010. PMID: 20551460 Clinical Trial.
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. Teml A, et al. Wien Klin Wochenschr. 2007;119(17-18):519-26. doi: 10.1007/s00508-007-0841-0. Wien Klin Wochenschr. 2007. PMID: 17943403
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Reinisch W, et al. Among authors: teml a. Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.
Adherence to thiopurine treatment in out-patients with Crohn's disease.
Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E, Schwab M. Bokemeyer B, et al. Among authors: teml a. Aliment Pharmacol Ther. 2007 Jul 15;26(2):217-25. doi: 10.1111/j.1365-2036.2007.03365.x. Aliment Pharmacol Ther. 2007. PMID: 17593067 Free article.
23 results